660 related articles for article (PubMed ID: 31848188)
1. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J
Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249
[No Abstract] [Full Text] [Related]
5. Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity.
Tumino N; Besi F; Martini S; Di Pace AL; Munari E; Quatrini L; Pelosi A; Fiore PF; Fiscon G; Paci P; Scordamaglia F; Covesnon MG; Bogina G; Mingari MC; Moretta L; Vacca P
Front Immunol; 2021; 12():803014. PubMed ID: 35116033
[TBL] [Abstract][Full Text] [Related]
6. New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.
Dufies M; Grytsai O; Ronco C; Camara O; Ambrosetti D; Hagege A; Parola J; Mateo L; Ayrault M; Giuliano S; Grépin R; Lagarde N; Montes M; Auberger P; Demange L; Benhida R; Pagès G
Theranostics; 2019; 9(18):5332-5346. PubMed ID: 31410218
[TBL] [Abstract][Full Text] [Related]
7. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
Clavijo PE; Friedman J; Robbins Y; Moore EC; Smith E; Zauderer M; Evans EE; Allen CT
Cancer Immunol Res; 2019 Feb; 7(2):282-291. PubMed ID: 30514791
[TBL] [Abstract][Full Text] [Related]
8. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.
Wang H; Nan S; Wang Y; Xu C
J Cell Mol Med; 2021 May; 25(10):4596-4607. PubMed ID: 33733587
[TBL] [Abstract][Full Text] [Related]
9. Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer.
Horinaka A; Sakurai D; Ihara F; Makita Y; Kunii N; Motohashi S; Nakayama T; Okamoto Y
Cancer Sci; 2016 Mar; 107(3):207-16. PubMed ID: 26679292
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
11. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
[TBL] [Abstract][Full Text] [Related]
12. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
[TBL] [Abstract][Full Text] [Related]
13. Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy.
Zalfa C; Paust S
Front Immunol; 2021; 12():633205. PubMed ID: 34025641
[TBL] [Abstract][Full Text] [Related]
14. Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck.
Chen WC; Lai CH; Chuang HC; Lin PY; Chen MF
Head Neck; 2017 Feb; 39(2):347-355. PubMed ID: 27696591
[TBL] [Abstract][Full Text] [Related]
15. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.
Horn LA; Riskin J; Hempel HA; Fousek K; Lind H; Hamilton DH; McCampbell KK; Maeda DY; Zebala JA; Su Z; Schlom J; Palena C
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188703
[TBL] [Abstract][Full Text] [Related]
17. Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.
Stiff A; Trikha P; Mundy-Bosse B; McMichael E; Mace TA; Benner B; Kendra K; Campbell A; Gautam S; Abood D; Landi I; Hsu V; Duggan M; Wesolowski R; Old M; Howard JH; Yu L; Stasik N; Olencki T; Muthusamy N; Tridandapani S; Byrd JC; Caligiuri M; Carson WE
Clin Cancer Res; 2018 Apr; 24(8):1891-1904. PubMed ID: 29363526
[No Abstract] [Full Text] [Related]
18. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
19. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
20. Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the
Kobayashi M; Chung JS; Beg M; Arriaga Y; Verma U; Courtney K; Mansour J; Haley B; Khan S; Horiuchi Y; Ramani V; Harker D; Gopal P; Araghizadeh F; Cruz PD; Ariizumi K
Clin Cancer Res; 2019 Jan; 25(2):828-838. PubMed ID: 30049749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
